Page last updated: 2024-10-25

cilostazol and Arterial Occlusive Diseases

cilostazol has been researched along with Arterial Occlusive Diseases in 33 studies

Arterial Occlusive Diseases: Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.

Research Excerpts

ExcerptRelevanceReference
" Among the key recommendations in this chapter are the following: For patients with chronic limb ischemia, we recommend lifelong aspirin therapy in comparison to no antiplatelet therapy in patients with clinically manifest coronary or cerebrovascular disease (Grade 1A) and in those without clinically manifest coronary or cerebrovascular disease (Grade 1C+)."4.82Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004)
"To evaluate the efficacy of oral administration of cilostazol, an antithrombotic agent, for the prevention of thrombotic occlusion and intimal hyperplasia after stenting."3.69Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. ( Kichikawa, K; Kimura, Y; Kubota, Y; Maeda, M; Makutani, S; Nishimine, K; Ohishi, H; Sakaguchi, S; Uchida, H; Yoshioka, T, 1995)
"Cilostazol is an antiplatelet, antithrombotic agent, which has been used for the treatment of PAOD."2.80Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. ( Chen, JH; Chuang, TJ; Hsiao, FC; Hsieh, CH; Hung, YJ; Lee, CH; Lin, TK; Liu, JS, 2015)
"Cilostazol (200 mg/day) was administered orally for 1 year to 13 patients with 16 lesions (nine symptomatic, seven asymptomatic) confirmed by DSA."2.76Efficacy of cilostazol for intracranial arterial stenosis evaluated by digital subtraction angiography/magnetic resonance angiography. ( Fujimoto, Y; Yamada, K, 2011)
" From a clinical point of view, Cilostazol is indicated in stage IIb of PAOD (Fontaine); its recommended dosage is 2x100 (reduced in case of moderate side effects, 2x50) mg with detectable prolongation of subjective (reported by the patient) and objective walking distance (but not in smokers [!]; ABI-based measurement of the effect not suitable) and partially with an improval of the quality of life (associated with a prolonged but steadily improving therapeutic effect from the 4th to the 6th week until the 6th to the 12th month)."2.48[Role of cilostazol in the sequential therapeutic spectrum of the peripheral arterial occlusion disease (PAOD)]. ( Halloul, Z; Meyer, F; Weber, M; Weber, T, 2012)
"Cilostazol is a phosphodiesterase inhibitor licensed for treating patients suffering from intermittent claudication."2.45A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. ( Dindyal, S; Kyriakides, C, 2009)
"Cilostazol (CLZ) was originally developed as a selective inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3)."2.42Cilostazol as a unique antithrombotic agent. ( Czerwiec, F; Kambayashi, J; Liu, Y; Shakur, Y; Sun, B; Yoshitake, M, 2003)
"Cilostazol was marketed first in Japan in 1988 and later in seven other countries for the treatment of chronic arterial occlusion."2.41[Research and development of cilostazol: an antiplatelet agent]. ( Kimura, Y; Nakagawa, K; Nishi, T, 2000)
"Cilostazol has also been reported to inhibit smooth muscle cell proliferation in vitro and has been demonstrated in a clinical study to favorably alter plasma lipids: to decrease triglyceride and to increase HDL-cholesterol levels."2.41Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. ( Kambayashi Ji, J; Liu, Y; Shakur, Y; Yoshitake, M, 2001)
"Cilostazol was administered at 200 mg/day for 6 successive weeks to 7 patients (10 lower limbs and 1 upper limb) and at 100 mg/day for 6 weeks to 2 patients (3 lower limbs) and 4 weeks to 1 (1 lower limb), and the skin temperature and skin blood flow were measured in the limbs of these patients."1.27Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. ( Hyakuna, Y; Iwatani, M; Morioka, Y; Ohashi, S, 1985)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19903 (9.09)18.7374
1990's3 (9.09)18.2507
2000's17 (51.52)29.6817
2010's10 (30.30)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kan, CD1
Wang, JN1
Li, WP1
Lin, SH1
Chen, WL1
Hsu, YP1
Yeh, CS1
Melzer, J1
Saller, R1
Warner, CJ1
Greaves, SW1
Larson, RJ1
Stone, DH1
Powell, RJ1
Walsh, DB1
Goodney, PP1
Liu, JS1
Chuang, TJ1
Chen, JH1
Lee, CH1
Hsieh, CH1
Lin, TK1
Hsiao, FC1
Hung, YJ1
Weber, M3
Weber, T2
Meyer, F3
Halloul, Z3
Dindyal, S2
Sharma, P1
Kyriakides, C2
Hsieh, CJ1
Wang, PW1
Soga, Y1
Iida, O2
Hirano, K1
Suzuki, K1
Kawasaki, D1
Miyashita, Y1
Tsuchiya, T1
Nobuyoshi, M1
Yamada, K1
Fujimoto, Y1
Graf, D1
Panteli, B1
Adolf, D1
Setacci, C1
Castelli, P1
Chiesa, R1
Grego, F1
Simoni, GA1
Stella, A1
Galzerano, G1
Sirignano, P1
De Donato, G1
Setacci, F1
Anand, S3
Creager, M3
Kambayashi, J1
Liu, Y2
Sun, B1
Shakur, Y2
Yoshitake, M2
Czerwiec, F1
Wilhite, DB1
Comerota, AJ1
Schmieder, FA1
Throm, RC1
Gaughan, JP1
Rao, AK1
Zolli, A1
Jelnes, R1
Clagett, GP1
Sobel, M1
Jackson, MR1
Lip, GY1
Tangelder, M1
Verhaeghe, R1
Gaddi, AV1
Cicero, AF1
Regensteiner, JG1
Stewart, KJ1
Nanto, S1
Uematsu, M1
Morozumi, T1
Kitakaze, M1
Nagata, S1
Kubota, Y1
Kichikawa, K1
Uchida, H1
Maeda, M1
Nishimine, K1
Makutani, S1
Sakaguchi, S2
Yoshioka, T1
Ohishi, H1
Kimura, Y4
Ishizaka, N1
Taguchi, J1
Ikari, Y1
Aizawa, T1
Togo, M1
Miki, K1
Kurokawa, K1
Ohno, M1
Priollet, P1
Carman, TL1
Fernandez, BB1
Nishi, T1
Nakagawa, K1
Kambayashi Ji, J1
Kawamura, K1
Fujita, S1
Tani, T1
Kamiya, T1
Ohashi, S1
Iwatani, M1
Hyakuna, Y1
Morioka, Y1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
Predicting Peripheral Arterial Disease in Men With Erectile Dysfunction[NCT00743613]175 participants (Actual)Observational2005-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

16 reviews available for cilostazol and Arterial Occlusive Diseases

ArticleYear
[Clinical studies in peripheral arterial occlusive disease: update from the aspects of a meta-narrative review].
    Forschende Komplementarmedizin (2006), 2013, Volume: 20 Suppl 2

    Topics: Arterial Occlusive Diseases; Cilostazol; Complementary Therapies; Humans; Intermittent Claudication;

2013
Cilostazol is associated with improved outcomes after peripheral endovascular interventions.
    Journal of vascular surgery, 2014, Volume: 59, Issue:6

    Topics: Arterial Occlusive Diseases; Cilostazol; Endovascular Procedures; Femoral Artery; Global Health; Gra

2014
A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
    Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:1

    Topics: Angioplasty; Arterial Occlusive Diseases; Cilostazol; Clinical Trials as Topic; Coronary Restenosis;

2009
[Role of cilostazol in the sequential therapeutic spectrum of the peripheral arterial occlusion disease (PAOD)].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:20

    Topics: Arterial Occlusive Diseases; Cilostazol; Dose-Response Relationship, Drug; Germany; Humans; Peripher

2012
Restenosis: a challenge for vascular surgeon.
    The Journal of cardiovascular surgery, 2012, Volume: 53, Issue:6

    Topics: Animals; Arterial Occlusive Diseases; Cilostazol; Constriction, Pathologic; Humans; Secondary Preven

2012
Peripheral arterial disease.
    Clinical evidence, 2002, Issue:7

    Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Cilostazol; Combin

2002
Cilostazol as a unique antithrombotic agent.
    Current pharmaceutical design, 2003, Volume: 9, Issue:28

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arterial Occlusive Diseases; Cilostazol; Clinical Tria

2003
Foot ulceration due to arterial insufficiency: role of cilostazol.
    Journal of wound care, 2004, Volume: 13, Issue:2

    Topics: Aged; Arterial Occlusive Diseases; Blood Vessel Prosthesis Implantation; Chronic Disease; Cilostazol

2004
Peripheral arterial disease.
    Clinical evidence, 2002, Issue:8

    Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Cilostazol; Combin

2002
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med

2004
[Treatment of peripheral obstructive artery disease: a battle that could be winned also with drugs?].
    Minerva cardioangiologica, 2005, Volume: 53, Issue:6

    Topics: Arterial Occlusive Diseases; Cilostazol; Drug Therapy, Combination; Europe; Glycosaminoglycans; Huma

2005
Established and evolving medical therapies for claudication in patients with peripheral arterial disease.
    Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:11

    Topics: Ankle; Arterial Occlusive Diseases; Blood Pressure; Brachial Artery; Cilostazol; Exercise Test; Exer

2006
[Arteriopathy of the lower limbs: toward a global medical care].
    La Revue de medecine interne, 1999, Volume: 20, Issue:6

    Topics: Angiography; Arterial Occlusive Diseases; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Cl

1999
A primary care approach to the patient with claudication.
    American family physician, 2000, Feb-15, Volume: 61, Issue:4

    Topics: Arterial Occlusive Diseases; Cilostazol; Exercise; Humans; Patient Education as Topic; Pentoxifyllin

2000
[Research and development of cilostazol: an antiplatelet agent].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2000, Volume: 120, Issue:12

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arterial Occlusive Diseases; Cilostazol; Clinical Tria

2000
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
    Cardiovascular drug reviews, 2001,Winter, Volume: 19, Issue:4

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Angioplasty, Balloon, Coronary; Animals; Arterial Oc

2001

Trials

6 trials available for cilostazol and Arterial Occlusive Diseases

ArticleYear
Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.
    Endocrine, 2015, Volume: 49, Issue:3

    Topics: Aged; Aged, 80 and over; Ankle Brachial Index; Arterial Occlusive Diseases; C-Reactive Protein; Cilo

2015
Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease.
    Circulation journal : official journal of the Japanese Circulation Society, 2009, Volume: 73, Issue:5

    Topics: Adiponectin; Aged; Aged, 80 and over; Ankle; Arterial Occlusive Diseases; Biomarkers; Blood Pressure

2009
Efficacy of cilostazol for intracranial arterial stenosis evaluated by digital subtraction angiography/magnetic resonance angiography.
    Advances in therapy, 2011, Volume: 28, Issue:10

    Topics: Adult; Aged; Angiography, Digital Subtraction; Arterial Occlusive Diseases; Cerebral Arteries; Cilos

2011
[Interims analysis of a prospective observational study on the use of cilostazol (Pletal®) in daily clinical vascularsurgical practice].
    Zentralblatt fur Chirurgie, 2011, Volume: 136, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Cilostazol; Exercise Test; Female; Foll

2011
Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.
    Journal of vascular surgery, 2003, Volume: 38, Issue:4

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Bleeding Time; Cilostazol; Clopidogrel; Drug Therapy, Co

2003
Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions.
    Journal of vascular surgery, 2008, Volume: 48, Issue:1

    Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Cilostazol; Female; Femoral Artery; Humans;

2008

Other Studies

11 other studies available for cilostazol and Arterial Occlusive Diseases

ArticleYear
Clinical ultrasound stimulating angiogenesis following drug-release from polymersomes on the ischemic zone for peripheral arterial occlusive disease.
    Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:7

    Topics: Angiogenesis Inducing Agents; Animals; Arterial Occlusive Diseases; Bronchodilator Agents; Cilostazo

2018
[Prospective, Systematic Observational Study on the Daily Use of Cilostazol (Pletal) in Clinical Vascular Surgical Practice - Significant Improvement of Walking Distance and Quality of Life for Patients with PAOD, Stage II b].
    Zentralblatt fur Chirurgie, 2015, Volume: 140, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Cilostazol; Disability Evaluation; Fema

2015
Regarding "Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions".
    Journal of vascular surgery, 2008, Volume: 48, Issue:5

    Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Cilostazol; Constriction,

2008
Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia.
    Journal of vascular surgery, 2011, Volume: 54, Issue:6

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Cilostazol; Female; Femo

2011
[Peripheral arterial occlusive disease (PAVK)].
    VASA. Zeitschrift fur Gefasskrankheiten, 2003, Volume: 32, Issue:3

    Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteries; Cilostazol; Evidence-Based Medicine; Ex

2003
How reliable is preliminary evidence?
    Journal of wound care, 2004, Volume: 13, Issue:4

    Topics: Arterial Occlusive Diseases; Chronic Disease; Cilostazol; Humans; Platelet Aggregation Inhibitors; R

2004
Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study.
    Investigative radiology, 1995, Volume: 30, Issue:9

    Topics: Administration, Oral; Animals; Arterial Occlusive Diseases; Cilostazol; Dogs; Embolization, Therapeu

1995
Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery.
    Atherosclerosis, 1999, Volume: 142, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Topical; Angioplasty, Balloon; Animals; Arteria

1999
Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency.
    Arzneimittel-Forschung, 1985, Volume: 35, Issue:7A

    Topics: Animals; Arterial Occlusive Diseases; Aspartate Aminotransferases; Azoles; Cilostazol; Creatine Kina

1985
Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities.
    Arzneimittel-Forschung, 1985, Volume: 35, Issue:7A

    Topics: Aged; Ankle; Arterial Occlusive Diseases; Azoles; Chronic Disease; Cilostazol; Fibrinolytic Agents;

1985
Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion.
    Arzneimittel-Forschung, 1985, Volume: 35, Issue:7A

    Topics: Aged; Arterial Occlusive Diseases; Azoles; Cilostazol; Dose-Response Relationship, Drug; Female; Fib

1985